Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker AVXL · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| May 4, 2025 | A Study of ANAVEX3-71 in Adults With Schizophrenia NCT06245213 · Schizophrenia ANAVEX3-71 oral capsules, Placebo oral capsules | AVXL Anavex Life Sciences Corp. | Phase 2 | Active, not recruiting | 71 | Jun 30, 2025 | Registry ↗ |
| Aug 12, 2024 | OLE of Phase 2b/3 Study ANAVEX2-73-AD-004 NCT04314934 · Alzheimer Disease ANAVEX2-73 | AVXL Anavex Life Sciences Corp. | Phase 2/3 | Completed | 300 | Jun 14, 2024 | Registry ↗ |
| Aug 21, 2023 | ANAVEX2-73 Study in Pediatric Patients With Rett Syndrome NCT04304482 · Rett Syndrome ANAVEX2-73 oral liquid, Placebo oral liquid | AVXL Anavex Life Sciences Corp. | Phase 2/3 | Completed | 92 | Jun 1, 2023 | Registry ↗ |
| Aug 1, 2022 | OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001 NCT04575259 · Parkinson Disease Dementia ANAVEX2-73 | AVXL Anavex Life Sciences Corp. | Phase 2 | Completed | 132 | May 31, 2022 | Registry ↗ |
| Jul 14, 2022 | ANAVEX2-73 for Treatment of Early Alzheimer's Disease NCT03790709 · Alzheimer Disease High dose ANAVEX2-73, Mid dose ANAVEX2-73 | AVXL Anavex Life Sciences Corp. | Phase 2/3 | Completed | 509 | Jun 30, 2022 | Registry ↗ |
| Jan 27, 2022 | ANAVEX2-73 Study in Patients With Rett Syndrome NCT03941444 · Rett Syndrome ANAVEX2-73, Placebo | AVXL Anavex Life Sciences Corp. | Phase 3 | Completed | 33 | Sep 30, 2021 | Registry ↗ |
| Jan 19, 2022 | Phase 1 Study of ANAVEX3-71 NCT04442945 · Healthy ANAVEX3-71, Placebo | AVXL Anavex Life Sciences Corp. | Phase 1 | Completed | 36 | Sep 30, 2021 | Registry ↗ |
| Jan 12, 2021 | Study of ANAVEX2-73 in Patients With Rett Syndrome NCT03758924 · Rett Syndrome ANAVEX2-73, Placebo | AVXL Anavex Life Sciences Corp. | Phase 2 | Completed | 31 | Oct 30, 2020 | Registry ↗ |
| Jan 12, 2021 | An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease NCT02756858 · Alzheimer's Disease ANAVEX2-73 | AVXL Anavex Life Sciences Corp. | Phase 2 | Completed | 21 | Nov 2020 | Registry ↗ |
| Oct 22, 2020 | ANAVEX2-73 Study in Parkinson's Disease Dementia NCT03774459 · Parkinsons Disease With Dementia High dose ANAVEX2-73, Mid dose ANAVEX2-73 | AVXL Anavex Life Sciences Corp. | Phase 2 | Completed | 132 | Sep 30, 2020 | Registry ↗ |
| Nov 28, 2018 | Phase 2a Dose Finding, PK/PD and 12 Month Exploratory Efficacy Study of ANAVEX2-73 in Patients With… NCT02244541 · Alzheimer's Disease ANAVEX2-73 Oral, ANAVEX2-73 Intravenous | AVXL Anavex Life Sciences Corp. | Phase 2 | Completed | 32 | Nov 2015 | Registry ↗ |
11 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 9:01 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances